Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2...

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Genetics

Background:

• Intensive glycemic control in the ACCORD study showed differential effects on coronary artery disease (CAD) based on haptoglobin (Hp) phenotype.
• The Hp2-2 phenotype's role in mediating the benefits of intensive glycemic control on cardiovascular outcomes requires further investigation across diverse populations.

Purpose of the Study:

• To evaluate the association between intensive glycemic control and major CAD events in the ADVANCE trial, stratified by Hp2-2 phenotype.
• To determine if demographic and clinical factors modify the effect of intensive glycemic control on CAD risk in relation to Hp phenotype.

Main Methods:

• A case-cohort study within the ADVANCE trial measured Hp phenotype in available samples.
• Weighted multivariable-adjusted Cox regression models analyzed the association between intensive glycemic control (HbA1c ≤6.5%) and major CAD events.
• Analyses were performed separately for participants with and without the Hp2-2 phenotype and stratified by sex, race, previous CVD, diabetes duration, and HDL-cholesterol.

Main Results:

• Overall, intensive glycemic control was not significantly associated with CAD risk in participants with or without the Hp2-2 phenotype.
• A significant reduction in CAD risk was observed with intensive therapy among participants with the Hp2-2 phenotype and no previous cardiovascular disease (HR 0.47, Pinteraction = 0.01).

Conclusions:

• Intensive glycemic control appears to prevent major CAD events in a specific subset of ADVANCE participants: those with the Hp2-2 phenotype and no prior CVD.
• These findings support the hypothesis that intensive glycemic control may be beneficial for cardiovascular event prevention in individuals with the Hp2-2 phenotype.